These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27529959)

  • 1. [GENERIC VARIETY AND MONITORING OF THE DRUG SENSITIVITY OF THE MYCOTIC MICROFLORA IN PATIENTS WITH BRONCHOPULMONARY DISEASES].
    Tuberk Biolezni Legkih; 2010; (3):49-52. PubMed ID: 27529959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs.
    Shobana CS; Mythili A; Homa M; Galgóczy L; Priya R; Babu Singh YR; Panneerselvam K; Vágvölgyi C; Kredics L; Narendran V; Manikandan P
    J Mycol Med; 2015 Mar; 25(1):44-9. PubMed ID: 25541256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.
    Mandras N; Roana J; Scalas D; Fucale G; Allizond V; Banche G; Barbui A; Li Vigni N; Newell VA; Cuffini AM; Tullio V
    New Microbiol; 2015 Oct; 38(4):583-7. PubMed ID: 26485018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vitro susceptibility of some mycotic agents to a new orally active triazole, itraconazole.
    Otcenásek M
    J Hyg Epidemiol Microbiol Immunol; 1990; 34(2):129-34. PubMed ID: 2170505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis.
    Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B
    Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
    Cuenca-Estrella M; Gomez-Lopez A; Gutierrez MO; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1062-5. PubMed ID: 18195057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility patterns of fungi isolated from horses with ulcerative keratomycosis.
    Brooks DE; Andrew SE; Dillavou CL; Ellis G; Kubilis PS
    Am J Vet Res; 1998 Feb; 59(2):138-42. PubMed ID: 9492925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates.
    Carrillo-Muñoz AJ; Brió S; Alonso R; del Valle O; Santos P; Quindós G
    Int J Antimicrob Agents; 2002 Nov; 20(5):375-9. PubMed ID: 12431873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
    Marangon FB; Miller D; Giaconi JA; Alfonso EC
    Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
    Pfaller MA; Diekema DJ
    J Clin Microbiol; 2004 Oct; 42(10):4419-31. PubMed ID: 15472288
    [No Abstract]   [Full Text] [Related]  

  • 17. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates.
    Carrillo-Muñoz AJ; Tur-Tur C; Hernández-Molina JM; Quindós G; Marcos-Arias C; Eraso E; Cárdenes D; Ortiz-Maestro O; Santos P; Estivill D; Guardia C; Giusiano G
    Rev Esp Quimioter; 2010 Sep; 23(3):122-5. PubMed ID: 20844842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility of emerging opportunistic yeasts and yeast-like fungi from Rhea americana.
    de Aguiar Cordeiro R; Pereira de Alencar L; Nogueira Brilhante RS; de Souza Collares Maia Castelo-Branco D; Cordeiro Teixeira CE; de Brito Macedo R; Teixeira Lima D; Paiva de Araújo Neto M; Jalles Monteiro A; Dutra Alves N; Franco de Oliveira M; Costa Sidrim JJ; Rocha Gadelha MF
    Can J Microbiol; 2013 Aug; 59(8):577-80. PubMed ID: 23899001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.